Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
Improved financials
Launch excellence
> High-value innovation
Operational excellence
Strengthen foundations
Conclusion
Abbreviations
3. High-value innovation
Key near-term readouts (2023 - 2024) for high value assets...
Kisqali
NATALEE trial in adjuvant breast cancer
testing both high-risk and intermediate-risk
patients with final Phase 3 readout
expected in 2023
Iptacopan
APPLY-PNH trial with expected Phase 3
readout in H2 2022, followed by other
indications in 2023
Pluvicto
PSMAfore trial in mCRPC (post-ARDT,
pre-taxane) with expected readout
end of 2022 / early 2023
PSMAddition trial in mHSPC with
expected readout in 2024
21
21
Remibrutinib
CSU Phase 3 REMIX-1 and -2 trials with
expected readout in 2024 and
Multiple sclerosis Phase 3 REMODEL-1
and -2 trials with expected readout in 2025
Scemblix
1L CML-CP trial with expected readout in
2024
Unprobabilized peak sales of indications in late-stage development:
> USD 1bn
> USD 2bn
> USD 3bn
Novartis Investor Presentation | September 22, 2022
1 |
NOVARTIS | Reimagining MedicineView entire presentation